PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada...
Read moreNegma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow...
Read moreTORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and...
Read moreHighly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemiaStudy...
Read more- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81%...
Read moreData shows that AMP-vaccination significantly enhanced TCR-T cell anti-tumor response while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid tumors in an...
Read moreSAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week...
Read more-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All Patients...
Read moreTORONTO, May 01, 2022 (GLOBE NEWSWIRE) -- Today marks the first day of Brain Cancer Awareness month. On this day Brain Cancer Canada grants $100,000 to the St. Michael's Hospital program...
Read moreNew data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from research on comorbidities associated with...
Read more